Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874562 · ClinicalTrials.gov registry record · Phase 1
Rapamycin in Relapsed Acute Lymphoblastic Leukemia
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT00874562 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 6 participants.
The verdict
NCT00874562, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a research study designed to look at the biological effects of two drugs on leukemia cells. In this study, we are comparing the effects of drugs called corticosteroids when used alone or with another drug called rapamycin. Rapamycin is a drug that prevents the body's immune system from working normally. It has been used for many years after kidney transplants to prevent rejection of the organ. Recent work suggests that rapamycin may also help treat leukemia and other cancers.
Interventions
- DRUG Corticosteroid
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2007-07 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00874562
The ClinicalTrials.gov registry entry for NCT00874562 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Corticosteroid is the first listed.
NCT00874562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00874562 about?
NCT00874562 is a clinical study titled "Rapamycin in Relapsed Acute Lymphoblastic Leukemia". This is a research study designed to look at the biological effects of two drugs on leukemia cells. In this study, we are comparing the effects of drugs called corticosteroids when used alone or with another drug called rapamycin. Rapamycin is a drug that prevents the body's immune system from worki...
What is the current status of trial NCT00874562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2007-07. Estimated completion is 2016-04.
What interventions are being tested in trial NCT00874562?
The interventions under investigation include: Corticosteroid (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT00874562?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.